Sulfated polysaccharide compound and the preparation and use thereof

Abstract

The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS). The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use.

1 - 118 . (canceled) 
     
     
         119 . A mixture comprising sulfated xylan molecules wherein sulfur is present in the molecules in an amount that is at least 17% of the molecular weight of the molecules. 
     
     
         120 . The mixture of  claim 119 , wherein sulfur is present in the molecules in an amount that is greater than about 18% of the molecular weight of the molecules. 
     
     
         121 . The mixture of  claim 119 , wherein sulfur is present in the molecules in an amount that is between about 17.1% and 18.5% of the molecular weight of the molecules. 
     
     
         122 . The mixture of  claim 119 , wherein sulfur is present in the molecules in an amount that is between about 18.2% and 18.5% of the molecular weight of the molecules. 
     
     
         123 . The mixture of  claim 119 , wherein the molecules comprise one or more linear 1-4 conjugated beta-D-xylose units and at least one 4-O-methyl-beta-D-glucuronic acid attached to carbon-2 of every about eight to ten xylose units. 
     
     
         124 . The mixture of  claim 119 , wherein the sulfated xylan molecules have molecular weights between about 1000 Da and about 6000 Da. 
     
     
         125 . The mixture of  claim 124 , wherein the sulfated xylan molecules have molecular weights between about 1000 Da and about 5000 Da. 
     
     
         126 . The mixture of  claim 125 , wherein the sulfated xylan molecules have molecular weights between about 1000 Da and about 4000 Da. 
     
     
         127 . The mixture of  claim 119 , wherein the sulfated xylan molecules have a mode molecular weight between about 1500 Da and about 3000 Da. 
     
     
         128 . The mixture of  claim 119 , wherein the sulfated xylan molecules are present in salt form. 
     
     
         129 . The mixture of  claim 128 , wherein the sulfated xylan molecules are present as sodium salts. 
     
     
         130 . A pharmaceutical composition comprising sulfated xylan molecules according to  claim 119 . 
     
     
         131 . A method for the treatment of a non-infective inflammatory disease, ischaemia, cancer, a viral disease, interstitial cystitis, Crohn's disease, ulcerative colitis, Reiter's syndrome, haematomas, haemorrhoids, frost bite or burns, in a subject in need thereof, the method comprising administration to the subject of a therapeutically effective amount of sulfated xylan molecules according to claim  1 , or a pharmaceutical composition according to  claim 130 . 
     
     
         132 . A method for the treatment of osteoarthritis in a subject in need thereof, the method comprising administration to the subject of a therapeutically effective amount of sulfated xylan molecules according to claim  1 , or a pharmaceutical composition according to  claim 130 .